- Home
- GHM vs ALT Comparison
GHM vs ALT Comparison
Compare GHM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- ALT
- Stock Information
- Founded
- GHM 1936
- ALT 1997
- Country
- GHM United States
- ALT United States
- Employees
- GHM N/A
- ALT N/A
- Industry
- GHM Industrial Machinery/Components
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- GHM Industrials
- ALT Health Care
- Exchange
- GHM Nasdaq
- ALT Nasdaq
- Market Cap
- GHM 480.7M
- ALT 529.9M
- IPO Year
- GHM N/A
- ALT N/A
- Fundamental
- Price
- GHM $46.66
- ALT $6.83
- Analyst Decision
- GHM Buy
- ALT Strong Buy
- Analyst Count
- GHM 1
- ALT 8
- Target Price
- GHM $35.00
- ALT $19.71
- AVG Volume (30 Days)
- GHM 88.3K
- ALT 2.5M
- Earning Date
- GHM 02-03-2025
- ALT 11-12-2024
- Dividend Yield
- GHM N/A
- ALT N/A
- EPS Growth
- GHM 172.71
- ALT N/A
- EPS
- GHM 0.71
- ALT N/A
- Revenue
- GHM $196,402,000.00
- ALT $52,000.00
- Revenue This Year
- GHM $13.21
- ALT N/A
- Revenue Next Year
- GHM $9.89
- ALT N/A
- P/E Ratio
- GHM $65.50
- ALT N/A
- Revenue Growth
- GHM 11.88
- ALT N/A
- 52 Week Low
- GHM $18.90
- ALT $5.28
- 52 Week High
- GHM $49.28
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- GHM 61.24
- ALT 41.57
- Support Level
- GHM $40.50
- ALT $6.19
- Resistance Level
- GHM $49.28
- ALT $7.83
- Average True Range (ATR)
- GHM 2.06
- ALT 0.39
- MACD
- GHM 0.05
- ALT -0.04
- Stochastic Oscillator
- GHM 70.16
- ALT 39.02
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.